Author: William Green

Omega-3 fatty acids have more clinical trial data behind them than almost any other supplement category, and in my reading of the major trials, that data tells a more complicated story than either enthusiastic supporters or categorical dismissers acknowledge. The evidence supports specific uses at specific doses in specific populations — not blanket supplementation for everyone, and not dismissal of the category based on trials that tested inadequate doses in the wrong populations.

The Two Major Clinical Trials

The REDUCE-IT trial, published by Bhatt et al. in the New England Journal of Medicine in 2019, tested high-dose icosapentaenoic acid only (Vascepa, as icosapent ethyl) at 4 grams per day in patients already on statins who had both elevated triglycerides (above 150 mg/dL) and established cardiovascular disease or diabetes with additional risk factors. The result was a 25% reduction in major adverse cardiovascular events compared to placebo — a substantial and statistically robust finding. However, the trial’s placebo choice — mineral oil — has been significantly controversial. Mineral oil appears to have been metabolically active rather than inert, raising LDL-C, CRP, and other markers in the placebo group and potentially exaggerating the apparent treatment benefit. This issue has not been fully resolved in the literature, meaning the true effect size of icosapent ethyl in this population remains uncertain even if the direction of benefit is likely real.

The VITAL study (Manson et al., 2019, NEJM) took a very different approach: testing a standard mixed EPA+DHA supplement at 1 gram per day in approximately 25,000 adults from the general population without prior cardiovascular disease. The primary endpoints — major cardiovascular events and cancer incidence — were not significantly reduced overall. However, secondary analyses showed significant reductions in total mortality, cardiovascular mortality, and heart attack in specific subgroups, including those who did not eat fish. The VITAL result should not be interpreted as “omega-3 does not work.” It should be read as “1 gram per day of mixed EPA+DHA does not reduce primary cardiovascular events in a general population without established disease.” Dose and population matter enormously in interpreting these trials.

EPA vs DHA: Different Roles

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are both long-chain omega-3 fatty acids but serve substantially different biological functions. EPA is the primary precursor to specialized pro-resolving mediators — resolvins, protectins, and maresins — that actively resolve inflammation rather than simply inhibiting its initiation. EPA also competes with arachidonic acid for COX and LOX enzymes, reducing pro-inflammatory prostaglandin and leukotriene production. The REDUCE-IT trial’s specific isolation of EPA is one reason its results are not directly generalizable to mixed EPA+DHA products.

DHA is primarily structural. It is highly concentrated in neuronal cell membranes and the retina, where its physical properties — high flexibility due to multiple double bonds — influence membrane fluidity and the function of embedded receptors and ion channels. DHA is particularly important during fetal brain development and in early childhood. For cardiovascular applications, the evidence slightly favors EPA; for neurological applications and during pregnancy, DHA has the stronger structural rationale.

Form Matters: Absorption Differences

The absorption of omega-3 fatty acids varies significantly by chemical form. In their natural state in fish, omega-3s exist in triglyceride (TG) form, attached to a glycerol backbone. This natural TG form has excellent bioavailability. Re-esterified triglyceride (rTG) supplements — where fish oil is processed and re-attached to a triglyceride backbone — also have excellent absorption and better oxidative stability than ethyl esters. Ethyl ester (EE) form is used in most pharmaceutical omega-3 products including Vascepa and the older Lovaza. Ethyl esters have lower bioavailability in a fasted state — roughly equivalent to natural TG when taken with a high-fat meal, but substantially lower without fat co-ingestion. The practical implication: if you take an ethyl ester omega-3 product, take it with your fattiest meal of the day. For supplement selection, rTG or natural TG form provides better absorption without that dependency.

Practical Dosing

For general health maintenance in individuals who eat fish fewer than twice per week, 1 to 2 grams of combined EPA+DHA daily from a quality rTG or natural TG source is a reasonable starting point supported by the background evidence from cohort studies and secondary analyses of major trials. For specific applications — triglyceride reduction, where the evidence for high-dose EPA or EPA+DHA is strongest — doses of 2 to 4 grams per day are used clinically, but at that range, medical supervision is appropriate given potential effects on bleeding time. The American Heart Association has recommended 1 gram per day EPA+DHA for patients with established coronary heart disease for years, though individual cardiologist guidance varies.

Where the Evidence Gets Complicated

Cognitive decline prevention is an area where omega-3 trials have been particularly inconsistent. Several large RCTs in older adults without cognitive impairment have not shown significant reductions in cognitive decline rates with supplementation, while some secondary analyses in populations with established deficiency have shown modest signals. The omega-3 index — a measure of EPA+DHA as a percentage of total red blood cell fatty acids — has been proposed as a cardiovascular risk biomarker, with indices below 4% associated with higher risk and indices above 8% considered protective. This is a promising research direction but is not yet part of standard clinical risk assessment protocols. For depression, a 2019 meta-analysis suggested modest benefit from EPA-dominant omega-3 supplementation in clinical depression, with less clear effects in prevention of depressive episodes in otherwise healthy individuals.

Not medical advice. Content is informational only. Consult a qualified healthcare provider before making changes to your health regimen.

Vitamin D occupies an unusual position in clinical nutrition: it is among the most deficient micronutrients in the developed world, its deficiency is frequently asymptomatic until severe, and there has been more disagreement over its optimal serum target level than almost any other nutrient. In my reading of the literature, the case for supplementation in appropriate populations is strong, the D3-K2 pairing has compelling mechanistic logic, and appropriate dosing requires attention to cofactors that is often missing from popular supplement guidance.

The Deficiency Landscape

Michael Holick’s 2007 landmark review in the New England Journal of Medicine documented vitamin D deficiency as a global problem, estimating that approximately 1 billion people worldwide had vitamin D deficiency or insufficiency. Among North Americans, NHANES analyses have consistently found that 40 to 50% have suboptimal 25(OH)D levels by most clinical definitions. The mechanism is clear: human skin produces vitamin D3 (cholecalciferol) when exposed to UVB radiation, but the UVB angle from the sun at latitudes above approximately 37 degrees north is insufficient for cutaneous synthesis during winter months — roughly October through March for most of the continental United States, and year-round further north. Indoor lifestyle reduces synthesis further regardless of latitude.

Highest-risk populations for deficiency include people living above 37 degrees north latitude during winter; people with darker skin (melanin absorbs UVB, requiring longer sun exposure for equivalent synthesis); indoor workers with minimal sun exposure; older adults (skin synthesis capacity decreases approximately 75% between age 20 and 70); and people with malabsorption conditions including Crohn’s disease and celiac disease, since dietary vitamin D requires fat for absorption in the small intestine.

Why D3 and K2 Work Together

Vitamin K2 has emerged as an important cofactor alongside vitamin D supplementation, and the rationale deserves careful explanation. One of vitamin D’s primary functions is increasing intestinal calcium absorption. However, calcium absorbed but not directed into bone and teeth can deposit in soft tissues, including arterial walls. Matrix Gla protein (MGP) is one of the primary inhibitors of vascular calcification, and it requires vitamin K2 — specifically the MK-7 form (menaquinone-7) — for activation via a carboxylation reaction. Osteocalcin, the protein responsible for incorporating calcium into bone matrix, similarly requires K2 for full activation.

The mechanistic concern, supported by animal studies and observational data, is that high-dose D3 supplementation without adequate K2 may increase circulating calcium without sufficient MGP and osteocalcin activation to direct it appropriately — potentially contributing to soft tissue calcification. Rizzoli and colleagues have published on the synergistic role of D3 and K2 in bone health. RCT evidence specifically isolating D3+K2 versus D3 alone in humans remains limited, but the mechanistic logic is sound enough that most clinicians familiar with this area recommend supplementing K2 alongside D3.

Who Needs to Supplement

Sun exposure remains the most efficient means of maintaining vitamin D status for those who can achieve it. Approximately 10 to 30 minutes of midday sun exposure on significant skin surface area during summer months in temperate latitudes produces 10,000 to 20,000 IU of vitamin D3 in lighter-skinned individuals — far more than dietary or supplemental sources typically provide. The problem is that this exposure is seasonal, latitude-dependent, and incompatible with consistent sun-protective behavior that is otherwise appropriate for skin cancer prevention. Dietary sources (fatty fish, egg yolks, fortified dairy) typically provide 100 to 400 IU per serving — meaningful but insufficient to maintain optimal levels without sun exposure for most people. A baseline 25(OH)D blood test before supplementing is genuinely useful: it is inexpensive, widely available, and allows dose calibration rather than guessing.

Target Levels and the Controversy

Laboratory reference ranges often flag 20 ng/mL (50 nmol/L) as the lower bound of sufficiency. Holick and a number of researchers working in this area argue that optimal function — particularly for immune regulation, neuromuscular performance, and cancer risk reduction — requires levels of 40 to 60 ng/mL (100 to 150 nmol/L) or higher. This remains contested; the Endocrine Society and many conventional guidelines set sufficiency at 20 ng/mL for bone health outcomes specifically. The VITAL trial (Manson et al., 2019, NEJM) tested 2,000 IU per day of vitamin D3 in approximately 25,000 general population adults and found no significant reduction in primary cardiovascular or cancer endpoints overall, though secondary analyses showed benefits in subgroups, including those who did not eat fish and those with lower baseline vitamin D levels.

Dosing and Cofactors

For individuals with identified deficiency (below 20 ng/mL), clinical repletion doses are typically 4,000 to 8,000 IU per day for 2 to 3 months, followed by maintenance. For insufficiency or as preventive supplementation in high-risk populations, 2,000 to 5,000 IU per day of D3 is the range most commonly used in research. K2 as MK-7 is typically supplemented at 100 to 200 mcg per day alongside D3. One frequently overlooked cofactor is magnesium: magnesium is required for the enzymatic hydroxylation steps that convert vitamin D3 into its active form (calcitriol). Magnesium-deficient individuals may not fully utilize vitamin D supplementation, making these two nutrients logical to address together.

Not medical advice. Content is informational only. Consult a qualified healthcare provider before making changes to your health regimen.

Magnesium is required as a cofactor in more than 300 enzymatic reactions in the human body — involved in ATP synthesis, DNA repair, nerve signal transmission, muscle contraction and relaxation, and the activation of vitamin D. Given this central role, what strikes me about the epidemiological data is how common inadequate magnesium intake has become in industrialized populations, and how underappreciated this deficiency remains in routine clinical practice.

The Deficiency Data

Rosanoff et al. published a comprehensive analysis in Nutrition Reviews in 2012 drawing on NHANES (National Health and Nutrition Examination Survey) data across multiple collection cycles, estimating that approximately 48% of Americans consume less than the estimated average requirement (EAR) for magnesium. The EAR is set at 320 to 330 mg per day for adult women and 350 to 360 mg per day for adult men; the Recommended Dietary Allowance is set somewhat higher to cover 97 to 98 percent of the population. Processing strips magnesium substantially: refined white flour contains roughly 78% less magnesium than whole wheat flour. Most Americans eat very little whole grain food and consume a diet dominated by refined and processed products with low mineral density.

Groups with particularly elevated risk for magnesium deficiency include people with type 2 diabetes (higher urinary magnesium losses from glycosuria-driven diuresis), people with alcohol use disorder, older adults (both reduced dietary intake and reduced GI absorption efficiency with age), individuals using proton pump inhibitors long-term (PPIs impair intestinal magnesium absorption), and people with celiac disease or Crohn’s disease where small intestinal absorption is compromised.

Forms of Magnesium: What the Bioavailability Research Shows

Not all magnesium supplements are equivalent, and the form matters substantially for both bioavailability and gastrointestinal side effects. Magnesium glycinate — magnesium bound to glycine — is a chelated form with high bioavailability and minimal laxative effect. The glycine component has independent relaxation effects via glycine receptors in the central nervous system, which may contribute to the sleep benefits attributed to this form. This is generally the preferred form for supplementation aimed at sleep quality or anxiety support.

Magnesium citrate, bound to citric acid, has good bioavailability and mild osmotic laxative effect at higher doses, making it useful for individuals with constipation and less ideal for those who are not. Magnesium malate, bound to malic acid, has good bioavailability and is frequently used in protocols for muscle fatigue, given malic acid’s role in the citric acid cycle. Magnesium oxide is the form to avoid for supplementation purposes: bioavailability has been measured at approximately 4% in some studies, meaning the large majority passes through the gut without absorption. It functions primarily as an osmotic laxative. Despite being the cheapest form and the most commonly included in low-cost multivitamins, it is poorly suited for addressing magnesium deficiency.

Clinical Applications with Evidence

Sleep quality has received meaningful attention in magnesium research. Nielsen et al. published findings in Magnesium Research in 2010 examining older adults with magnesium deficiency and found that supplementation improved sleep efficiency, total sleep time, and early morning awakening, alongside reductions in inflammatory markers including IL-6 and CRP. The sample size was modest (n=100), which is a genuine limitation, but the mechanistic basis is credible: magnesium regulates GABA receptors — the primary inhibitory neurotransmitter system — and melatonin secretion, and deficiency has been associated with hyperactivation of the sympathetic nervous system and elevated cortisol.

The cardiovascular evidence is primarily epidemiological. Volpe (2013, Advances in Nutrition) reviewed the relationship between magnesium status and cardiovascular disease, finding consistent associations between higher magnesium intake and reduced risk of hypertension, coronary artery disease, and type 2 diabetes across multiple cohort studies. Magnesium regulates vascular smooth muscle tone and has calcium antagonist-like effects on arterial function. RCT evidence for blood pressure reduction with supplementation is positive but modest and most consistent in individuals with baseline deficiency.

Dosing: Elemental vs Salt Weight

A frequent source of confusion is the difference between elemental magnesium content and the weight of the magnesium salt listed on the label. Magnesium glycinate is approximately 14% elemental magnesium by weight, meaning a 400 mg capsule of magnesium glycinate delivers roughly 56 mg of elemental magnesium. Magnesium citrate is approximately 16% elemental magnesium. Clinical recommendations from the literature typically reference elemental magnesium doses in the range of 200 to 400 mg per day. When comparing products, always compare elemental magnesium, not salt weight. Quality supplement brands list both; cheaper products display only the salt weight on the front label.

Testing: Why Serum Levels Can Mislead

Standard serum magnesium tests are a poor proxy for magnesium status. Approximately 99% of the body’s magnesium is intracellular — located in bone, muscle, and soft tissue — with only about 1% in serum. The body tightly regulates serum magnesium through bone and muscle release, meaning serum levels remain in the reference range until tissue stores are substantially depleted. RBC magnesium, which measures magnesium within red blood cells, is a more accurate reflection of intracellular status and is ordered by some integrative physicians, though it is not routinely available in standard clinical panels. The practical implication: a normal serum magnesium result does not rule out deficiency.

Not medical advice. Content is informational only. Consult a qualified healthcare provider before making changes to your health regimen.